Adverum Biotechnologies, Inc. (ADVM)
NASDAQ: ADVM · Real-Time Price · USD
2.870
-0.090 (-3.04%)
Apr 23, 2025, 4:00 PM EDT - Market closed

Adverum Biotechnologies Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Net Income
-130.93-122.12-154.54-145.54-117.51
Upgrade
Depreciation & Amortization
3.655.646.534.654.16
Upgrade
Loss (Gain) From Sale of Assets
00.050.12--
Upgrade
Asset Writedown & Restructuring Costs
--2.121.06-
Upgrade
Loss (Gain) From Sale of Investments
-1.91-1.94-0.882.770.52
Upgrade
Stock-Based Compensation
14.3517.5720.0825.1920.39
Upgrade
Other Operating Activities
21.4618.392.62-0.030.42
Upgrade
Change in Accounts Payable
-0.26-0.370.85-1.611.59
Upgrade
Change in Other Net Operating Assets
1.17-8.14155.6711.14
Upgrade
Operating Cash Flow
-92.46-90.9-108.09-107.83-79.29
Upgrade
Capital Expenditures
-0.39-0.81-11.82-15.12-11.84
Upgrade
Investment in Securities
-41.597.68153.5493.83-268.32
Upgrade
Investing Cash Flow
-41.8996.88141.7278.71-280.17
Upgrade
Long-Term Debt Repaid
----0.24-0.06
Upgrade
Net Debt Issued (Repaid)
----0.24-0.06
Upgrade
Issuance of Common Stock
1200.490.612.64358.09
Upgrade
Repurchase of Common Stock
-----2.04
Upgrade
Other Financing Activities
--0.42---
Upgrade
Financing Cash Flow
1200.070.612.4355.99
Upgrade
Net Cash Flow
-14.356.0434.24-26.73-3.47
Upgrade
Free Cash Flow
-92.85-91.71-119.91-122.95-91.14
Upgrade
Free Cash Flow Margin
-9285.00%-2547.50%--1639.39%-
Upgrade
Free Cash Flow Per Share
-4.69-9.10-12.08-12.54-10.70
Upgrade
Levered Free Cash Flow
-66-63.92-72.63-80.16-54.76
Upgrade
Unlevered Free Cash Flow
-66-63.92-72.63-80.16-54.76
Upgrade
Change in Net Working Capital
-3.365.74-6.524.21-6.25
Upgrade
Updated Apr 15, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q